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doi:10.1016/j.jtcvs.2003.12.0131388 The Journal of Thoracic and CardBackground: Prosthetic valve thrombosis is a life-threatening complication. We
reviewed the incidence, risk factors, and treatment strategies of this rare complica-
tion.
Methods: From February 1981 through January 2001, 5430 valve operations were
performed in 4924 patients at the Montreal Heart Institute. Of this cohort, 39
patients presented with prosthetic valve thrombosis and had complete follow-up
data obtained from our prospective valve clinic database.
Results: In this series 82% of patients were women, and the mean age was 58  11
years. The underlying pathology involved the mitral valve in 75% of cases. Most
prosthetic valve thromboses occurred with mechanical prostheses (95%). The time
interval from first valve replacement to prosthetic valve thrombosis was 39  42
months. The most frequent clinical presentation was severe congestive heart failure
(44%). On prosthetic valve thrombosis presentation, the international normalized
ratio was less than 2.5 in 54%, with inadequate anticoagulation management in 26%
and poor compliance in 26%. Eighty-two percent of patients underwent a surgical
procedure, consisting of thrombectomy in 47%, mitral valve replacement in 47%,
and aortic valve replacement in 6% of patients. The 30-day operative mortality and
total in-hospital mortality after prosthetic valve thrombosis were 25% and 41%,
respectively. The 10-year actuarial survival after prosthetic valve thrombosis was
46%  10%.
Conclusion: Inadequate level of anticoagulation is the most important factor in-
volved in the pathogenesis of prosthetic valve thrombosis. The overall mortality rate
despite surgical treatment remains high. This study underscores the importance of
meticulous surveillance of anticoagulation therapy in patients with prosthetic
valves.
Prosthetic valve thrombosis (PVT) is defined by any thrombus, in theabsence of infection, attached to or near an operated valve, occludingpart of the blood flow or interfering with valvular function.1 This rarebut life-threatening complication of prosthetic valve replacement isdependent on valve design (tilting disc valves and caged ball valves),structure (mechanical valves), and location (mitral position) and pa-
tient compliance with oral anticoagulation. The 11-year probability of PVT is 0.01%
to 0.02% for patients with either type of valve in the mitral or aortic position.2
Tilting disc mechanical valves3 have most often been implicated, although this
complication can be found with any type of valve prosthesis. Diagnosis is often
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CDestablished late and sometimes only at autopsy.4 Multiple
causes ranging from inadequate anticoagulation5,6 to pannus
formation7 have been identified. Surgical treatment includes
thrombectomy and valve replacement.
The purpose of this report is to review the clinical
experience with the medical and surgical management of
PVT in a large surgical cohort of patients undergoing valve
replacement at the Montreal Heart Institute.
Materials and Methods
From February 1981 through January 2001, 5430 valve operations
were performed in 4924 patients. From this cohort, 39 (0.8%)
patients were rehospitalized for PVT. The clinical records prospec-
tively gathered by a specialized team at the local valve clinic were
reviewed. Preoperative clinical data, initial valve procedure, diag-
nostic features of valve thrombosis, and management before, dur-
ing, and after the operation were recorded. The incidence of valve
thrombosis according to valve localization was analyzed. Several
factors were analyzed to define the risk factors for PVT develop-
ment, including sex, aortic versus mitral position, and single-
versus double-valve replacement.
Clinical Data at the Initial Operation
Thirty-nine patients presented with PVT, 7 (18%) men and 32
(82%) women (Table 1). Mean age at the time of PVT diagnosis
was 58  11 years. Sixteen (41%) patients were in atrial fibrilla-
tion before the initial valve replacement, and 4 (10%) patients had
a permanent pacemaker. Thirty-four (87%) patients were in New
York Heart Association (NYHA) functional class III or IV before
the first valve replacement. The initial pathology involved the
mitral valve in 29 (75%) cases, whereas aortic valve disease and
double-valve disease (mitral and aortic) accounted for 4 (10%) and
6 (15%) patients of the cohort, respectively. The first valve re-
placement was a redo intervention in 8 (21%) patients. Eleven
(28%) patients presented with a history of prior thromboembolic
complications, including retinal artery thrombosis, leg ischemia,
stroke, pulmonary embolism, or left atrial appendage thrombosis.
At least one risk factor for thromboembolism (coagulation
disorder, autoimmune systemic disease, or neoplasia) was present
in 7 (18%) patients. Lupus erythematosus was diagnosed in 2
patients.
Left atrial diameter measured by means of echocardiography
was 53  13 mm at the time of the first intervention. Preopera-
tively, cardiac dyskinesia was identified in 13 (33%) patients by
means of transthoracic echocardiography (TTE) or ventriculogra-
phy.
Initial Valve Surgery
Most initial valve replacements were performed with Carbomedics
prostheses (72%), including one patient having a tricuspid valve
replacement with a Carbomedic prosthesis for severe tricuspid
regurgitation. Left atrial appendage resection was performed in 2
(5%) patients. Postoperative left ventricular ejection fraction was
greater than 45% in most patients (26/31 [84%]). Mean initial
intensive care unit length of stay was 5  4 days, and mean
hospital stay was 13  7 days.
The Journal of ThoracicAnticoagulation Protocol
Anticoagulation was initiated 48 hours after all valvular proce-
dures (heparin and warfarin). When aspirin was added to the
anticoagulation regimen, it was started on postoperative day 1.
Patients were discharged with an international normalized ratio
(INR) in the target range of 2.5 to 3.5 and were followed at the
anticoagulation clinic.
Statistical Analysis
Data are expressed as means  SDs or medians when appropriate.
Univariate analysis was performed with the Student t test for
parametric data and the Pearson 2 test for proportions. Analysis of
survival was performed by using the Kaplan-Meier method. The
statistical analyses were performed with NCSS 2001 (NCSS Sta-
tistical Software, Kaysville, Utah).
Results
Thrombosis
The distribution of PVTs according to the site of valve
implantation was as follows: 26 (67%) mitral, 6 (15%)
aortic, 6 (15%) double, and 1 (3%) tricuspid replacement.
PVT involved mechanical prostheses in 25 (96%) of 26
instances in the mitral position and in 5 (83%) of 6 valves
in the aortic position. The only thrombosis of a tricuspid
valve was with a mechanical prosthesis.
Among double-valve prosthesis recipients (6 patients),
PVTs were in the mitral prosthesis in 5 (83%) patients, and
a bivalvular thrombosis was seen in 1 (17%) patient. In the
mitral valve replacement group, more patients had atrial
fibrillation than in the aortic valve replacement group (46%
vs 0%, P  .04). In the aortic position only 50% (3/6) were
considered eligible for a surgical procedure after PVT di-






Coronary artery disease 6 (15)
Hypertension 8 (21)
Diabetes 2 (5)
Preoperative rhythm (initial intervention)
Atrial fibrillation 16 (41)
Pacemaker 4 (10)
Preoperative NYHA class (initial intervention)




Mitral and aortic 6 (15)
Prior thromboembolism 11 (28)
Presence of a thromboembolism risk factor 7 (18)
NYHA, New York Heart Association.agnosis versus 88% (23/26) in the mitral position (P .03).
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The mean interval between the first valve replacement and
the occurrence of PVT was 39  42 months (range, 0-120
months). There were 8 (21%) early thromboses (30 days
after the first valve replacement) and 31 (79%) late throm-
boses. The median time between the diagnosis of PVT and
surgical treatment was 2 days (range, 0-138 days; 2 days in
late PVT and 2.5 days in early PVT).
Symptoms at presentation were dyspnea in 22 (56%)
patients, modification of heart murmur in 5 (13%) patients,
cardiogenic shock in 5 (13%) patients, and miscellaneous
symptoms (abdominal pain, syncope, or stroke) in 6 (15%)
patients. In one patient PVT was a fortuitous echocardio-
graphic finding. The majority of patients (34 [87%]) with
PVT were in NYHA functional class III or IV at the time of
diagnosis. Two patients were in respiratory-cardiac arrest,
and 1 patient was undergoing mechanical ventilation and
considered to be NYHA functional class IV. Overall, the
most frequent clinical finding was congestive heart failure
(17 [44%] patients). Occurrence of thromboembolism
(stroke or limb or organ ischemia) between initial valve
replacement and the occurrence of valve thrombosis was
reported in 9 (23%) patients.
The diagnosis of PVT was made with TTE in 21 (54%)
patients, transesophageal echocardiography in 8 (21%) pa-
tients, and angiography in 3 (8%) patients. The diagnosis
was established in 2 (5%) patients in the operating room and
in 5 (13%) patients at postmortem examination. The INR
recorded at the time of thrombosis was less than 2.5 in 21
(54%) patients (Table 2).
Precipitating Factors of PVT
PVT occurred during preparation or recovery from another
TABLE 2. Diagnosis of valve thrombosis
No. of
patients (%)
Early thrombosis (30 d) 8 (21)







Prior thromboembolism 9 (23)
INR 2.5 during thrombosis 21 (54)
Trigger factor
Compliance 10 (26)
Perioperative of another procedure 10 (26)
Dysrhythmia 2 (5)
Multiple causes 9 (23)
Unknown 8 (20)
INR, International normalized ratio.surgical procedure, requiring changes in the anticoagulant
1390 The Journal of Thoracic and Cardiovascular Surgery ● Matreatment and level in 10 (26%) patients. Poor patient com-
pliance with the anticoagulant treatment leading to lower
INR than recommended was responsible for another 10
(26%) PVT episodes. New atrial arrhythmias (atrial fibril-
lation) were observed in 2 (5%) other patients with PVT.
Multiples factors were probably operative in 9 (23%) pa-
tients specifically related to the association of poor compli-
ance and the appearance of a new atrial arrhythmia. No
specific cause was identified in 8 (21%) patients.
Atrial fibrillation was present in 45% (14/31) of patients
with late valve thrombosis versus 25% (2/8) of those with
early PVT (P  .01). Pannus formation was present along
with the thrombus at the time of the operation in 50%
(19/38) of patients, and this was more frequent in those with
late valve thrombosis (18/30 [60%]) than in those with early
PVT (1/8 [13%]; P  .01).
Thrombus
The characteristics of thrombi were reviewed in 38 of 39
patients. Thrombi were found in the left atrium in 16 (16/38
[42%]) patients, in the left ventricular cavity in 1 (1/38
[3%]) patient, and in both cavities in 21 (21/38 [55%])
patients. In patients with aortic valve thrombosis, 29% (2/6)
had thrombi on the aortic side only, and 71% (4/6) had
thrombi in the left ventricle.
Pathologic findings showed that the thrombus was fresh
in 34% (13/38), old in 13% (5/38), and had both character-
istics in 53% (20/38) of patients. Old and fresh thrombi
were defined according to pathologic structural organiza-
tion.
Thrombi were larger than 5 mm in 89% (34/38), mobile
in 58% (22/38), and obstructive in 89% (34/38).
Management of Patients With PVT and Early
Mortality
All patients were started on intravenous heparin as soon as
the diagnosis was suspected. Six (15%) of 39 patients re-
ceived thrombolytic therapy during 23  21 hours (range,
0-48 hours) by using streptokinase in 5 patients and rTPA in
another patient. Thrombolysis was attempted as a definitive
treatment in 5 (83%) patients because of the poor general
medical condition of the patients. In 1 patient thrombolysis
was used to allow an improvement of cardiac performance
to enable the transfer to our tertiary care center.
In the thrombolysis group (n 6), 2 (33%) patients died,
one from cardiogenic shock and one from hemorrhagic
stroke. Three (50%) patients were redirected toward surgi-
cal intervention after failure of thrombolysis, and another
was transferred to the operating room while receiving the
thrombolytic treatment.
Overall, 5 patients died before reaching the operating
room in the earlier part of the experience. The thrombotic
event occurred before the use of thrombolysis.
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operations without prior thrombolysis, and 4 patients un-
derwent operations after thrombolysis. Two patients died
immediately on chest opening without possible resuscita-
tion, and one patient could not be weaned from cardiopul-
monary bypass (3/32 [9%]).
A redo median sternotomy was used in 27 (84%) of 32
patients, and a right anterolateral thoracotomy was per-
formed in 5 patients. Video-assisted thrombectomy of the
prosthesis was performed in 14 (47%) of 30 patients treated
surgically, and valve replacement was required in 16 (53%)
of 30 patients. When the thrombosed prosthetic valve was
replaced, simultaneous thrombectomy of cardiac cavities
was performed. One patient had a mitral replacement and a
concomitant thrombectomy of the right atrium. Among the
16 patients who underwent valve replacement, 14 had mitral
valve replacement and 2 underwent aortic valve replace-
ment. All patients with early PVT underwent video-assisted
thrombectomy without the necessity for valve replacement.
The crossclamping time averaged 75  32 minutes (range,
16-133 minutes), and the cardiopulmonary bypass time was
118  48 minutes (range, 31-217 minutes).
The operative mortality rate was 9% (3/32). Overall,
hospital mortality of all patients with valve thrombosis was
41% (16/39). The overall hospital mortality was higher in
the early PVT group (6/8 [75%]) compared with that in the
late PVT group (10/31 [32%]; P  .03).
Cardiac complications occurred in 14% (4/29; low car-
diac output, cardiogenic shock, complete atrioventricular
block, and tamponade), 21% (6/29) presented with multiple
organ dysfunction, 10% (3/29) experienced a neurologic com-
plication (stroke), and coagulopathy occurred in 7% (2/29).
Postoperative Care
The oral anticoagulation regimen after surgical treatment of
PVT consisted of warfarin alone in 14 (14/25 [56%]) pa-
tients and a combination of warfarin and aspirin in 11
(11/25 [44%]) patients (dose range, 80-325 mg die). The
mean hospital stay was 13  9 days (range, 3-48 days), and
the mean intensive care unit stay was 7  9 days (range,
1-48 days).
Long-term Survival and Recurrence of PVT
The 10-year actuarial survival rate was 46% 10% (Figure
1). The cause of long-term death was sudden death in 3
patients. Three patients had recurrence of valve thrombosis
and died (2 after rereplacement and one after thrombec-
tomy). Two had severe left ventricular dysfunction, and one
had a hypercoagulation status associated with an autoim-
mune disease.
Among the 14 patients who underwent prosthetic throm-
bectomy, 8 remain long-term survivors without valvular
reintervention.
The Journal of ThoracicDiscussion
The present study suggests that surgical intervention should
be performed in most patients with PVT after the shortest
possible delay between diagnosis and the intervention.
Thrombolysis appears only useful as a medical bridge to an
operation. PVT thrombolysis did not have a good rate of
success in our group of patients as a primary treatment. The
second observation of this study is that PVT could be
prevented in most patients with better management of the
anticoagulation treatment.
Valve thrombosis is a rare but lethal complication of
valvular prosthetic replacement.8,9 The clinical presentation
varies from insidious dyspnea to cardiac arrest. Establishing
the diagnosis might be quite difficult, and some series have
been reported as being made at postmortem examination in
up to 50% of cases.4 In a recent study the delay between first
symptoms to hospitalization ranged from 1 to 45 days.10
Previous studies have shown that a delay in diagnosis and
long duration of symptoms resulted in a higher mortality.11
Clinical examination is a poor diagnostic tool.12 A normal
TTE scan with a strong clinical suspicion of PVT dictates an
extensive investigation with transesophageal echocardiog-
raphy.13
Mechanical valves, tilting disc vales, caged ball valves,
mitral position, and poor patient compliance with the anti-
coagulation treatment are the most frequently related risks
factors for PVT reported in the literature. Buttard and col-
leagues10 found inadequate systemic oral anticoagulation at
the time of diagnosis in 45%: 27% for medical reasons
(surgical intervention, neurologic events, or pregnancy) and
17% because of poor patient compliance. A direct relation-
ship has already been established between inadequate anti-
coagulation and valve thrombosis by several authors, as is
suggested in the present study.14-16
Early PVT was associated with a worse prognosis and
significantly higher in-hospital rates compared with those
with late occurrence of the thrombotic event.
Pannus formation, defined as an excessive wound fibro-
Figure 1. Survival after initial valve replacement surgery.sis around a prosthetic valve, has recently been studied in
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as early as the first postoperative month.10 In the present
series the precise role of pannus in the pathogenesis of valve
thrombosis remains unknown, but it was found to be more
frequent in female patients, in patients with late thrombosis,
and in survivors. The presence of pannus was correlated
with a better prognosis and is a definite indication for
prosthetic valve rereplacement.
Several studies have examined the role of thrombolysis
in the management of PVT.18,19 Recently, Roudaut and
coworkers20 conducted a retrospective study of 110 patients
treated with fibrinolytic therapy and concluded that the
treatment should be reserved for selected patients (those
with tricuspid thrombosis, critically ill patients, and patients
with contraindications to surgical intervention).
In our experience thrombolysis is indicated in those who
could not tolerate cardiopulmonary bypass and those with
severe hemodynamic compromise to improve cardiac func-
tion and to allow transfer to a tertiary care center for
definitive surgical treatment.
On the basis of the present experience, patients with PVT
should undergo emergency surgery. Valve thrombectomy is
performed in patients with fresh thrombi related to recent
change in the anticoagulation management, and valve re-
placement is done in all other patients. If patient compliance
with the medication at long term is an issue, a bioprosthetic
valve should be implanted. When thrombectomy is per-
formed, the ventricular cavity is inspected with a videotho-
racoscope.21 A laryngeal mirror can also be useful in this
situation. Prosthetic thrombectomy is a safe, rapid, and
simple procedure in a limited number of patients. Before
discharge, aspirin (80-325 mg die) is added to warfarin
treatment. By optimizing the level of anticoagulation and by
helping endothelialization of the prosthetic valve, aspirin
might improve survival.
Mortality in patients with PVT remains high. The most
common precipitating factors for valve thrombosis are in-
adequate anticoagulation and poor patient compliance, un-
derscoring the need for both patient- and physician- oriented
education. Although less invasive than surgical interven-
tion, thrombolysis can be reserved for patients necessitating
transfer to a tertiary care center. Surgical intervention re-
mains the mainstay of treatment for patients with PVT.
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